Clinical Review

Safety and Efficacy Comparison of Maximum Dose Simvastatin vs Rosuvastatin

Author and Disclosure Information

Heart disease remains the leading cause of death in the U.S., and studies have shown that elevated low-density lipoprotein cholesterol (LDL-C) is a major cause of coronary artery disease (CAD).(1-5) Lipid-lowering therapy, including simvastatin and rosuvastatin, has an important role in the reduction of LDL-C and primary and secondary prevention of CAD.(6) Within the VA Health Care System (VAHCS), simvastatin plays a major role in lipid management, because it is a formulary agent.


 

Recommended Reading

Aspirin for primary prevention of CVD: Are the right people using it?
Federal Practitioner
Joint Injections Don't Raise Bleeding Risk
Federal Practitioner
Measuring and Improving the Quality of Oral Anticoagulation for Veterans
Federal Practitioner
Gel Implant Relieves Sciatica; Antidepressants for Heart Failure Patients—Are There Benefits?; Chelation: Long Established, but Is It Safe?
Federal Practitioner
Leukocytosis After ICD Implantation; A Misleading Case of Herpes; Calculating the Risks of C difficile; Keeping Weight Off: A Losing Battle?
Federal Practitioner
Sleep Disorder Plus Diabetes Equals Cardiac Events?
Federal Practitioner
Disparities in Adherence; Preventive Dutasteride in Asymptomatic BPH; Antioxidants and Heart Failure; A Faster Way to Get Back to Sleep?
Federal Practitioner
Silent MI More Common Than Suspected; FDA Approves First A1C Test for Diagnosing Diabetes; Cash Back for Eating Better; Counting the Real Calories
Federal Practitioner
Competing Cardiovascular Outcomes
Federal Practitioner
Sitagliptin's Safety; New Option Approved for Hospital-Acquired Pneumonia; FDA Approves First Nonhormonal Drug for Menopause Symptoms
Federal Practitioner